The global contrast media injectors market is expected to reach USD 636.1 million by 2021. Factors such as increasing number of approvals for contrast agents, increasing number of public and private diagnostic centers, technological advancements in the contrast media injector arena and the increased focus of market players in the injector technology provide high growth opportunities for players in the global contrast media injectors market.
Interventional cardiology segment to grow at the highest CAGR during the forecast period
On the basis of application, the global contrast media injectors market is segmented into interventional radiology, and interventional cardiology applications. The radiology segment is expected to account for the largest share of the global contrast media injectors market whereas the interventional cardiology segment is expected to grow at the highest CAGR. The growth of the market can be attributed to the high global CVD burden. According to the World Heart Federation (WHF), by 2030, nearly 23.6 million people are predicted to die worldwide from CVD. This is leading to an increase in the demand for cardiac intervention procedures and coronary diagnostic procedures.
Key players in the global contrast injectors market include Bracco Imaging S.p.A. (Italy), Bayer HealthCare (Germany), Guerbet Group (France), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), GE Healthcare (U.S.), AngioDynamics (U.S.), Nemoto Kyorindo Co., Ltd. (Japan), Sino Medical- Device Technology Co., Ltd. (China), VIVID IMAGING (China), and Apollo RT Co., Ltd. (China).
No comments:
Post a Comment